36 results about "Agalactosis" patented technology

The invention provides an SNP (Single Nucleotide Polymorphism) site combination for identifying streptococcicosis resistance of tilapia and application of the SNP site combination. DNAs of tilapia tail fin tissues attacked by streptococcus agalactiae are re-sequenced, resistant and sensitive individuals of a tilapia population are screened, GWAS analysis is carried out, SNPs sites related to tilapia streptococcus agalactiae disease resistance are identified, functional gene annotation and enrichment analysis are carried out, two SNP sites LG1320881657 and LG1320548718 are screened, and the SNP sites related to tilapia streptococcus agalactiae disease resistance are obtained. The GG genotype of the LG1320881657 and the TT genotype of the LG1320548718 are the dominant genotypes related to the streptococcus agalactiae disease resistance of the tilapia mossambica. The tilapia mossambica resistant to streptococcosis is successfully screened by utilizing the two SNPs sites, effective SNPs are provided for developing tilapia mossambica anti-streptococcosis molecular marker-assisted breeding, excellent characters of parents are ensured, and the breeding efficiency is improved.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention discloses a rapid streptococcus agalactiae detection kit based on RPA (recombinase polymerase amplification) and CRISPR-Cas12a (clustered regularly interspaced short palindromic repeats) and application of the rapid streptococcus agalactiae detection kit. The rapid streptococcus agalactiae detection kit comprises an amplification primer of a recombinase polymerase amplification technology, CRISPR RNA (ribonucleic acid), an ssDNA (single-stranded deoxyribonucleic acid) probe and Cas12a protein Wherein an upstream primer sequence of an amplification primer of the recombinase polymerase amplification technology is as shown in SEQ ID NO: 1; and the sequence of the downstream primer is as shown in SEQ ID NO: 2. According to the invention, rapid, sensitive, accurate and specific detection of streptococcus agalactiae is realized.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

The invention provides application of baicalin in preparation of a medicine for treating streptococcus agalactiae induced mastitis, and relates to the technical field of medicine. A mouse is selected as an animal model to research the intervention effect and mechanism of the baicalin on the streptococcus agalactiae induced mouse mastitis inflammatory response, and it is clear that the baicalin can play a role in protecting the mouse mammary gland by regulating and controlling an NLRP3 inflammatory small body pathway; a reference basis is provided for treating the cow mastitis caused by streptococcus agalactiae infection by applying the baicalin.

The invention discloses application of carbazole derivatives C1-1 to C1-12, C2-1 to C2-5, C3-1 to C3-10, C4-1 to C4-3 and C5-1 to C5-2 to prevention and treatment of pathogenic bacteria of cow mastitis, and belongs to the field of natural medicinal chemistry. The compound disclosed by the invention has good inhibitory activity on the pathogenic bacteria, such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957 and Staphylococcus aureus, of the mastitis of the dairy cow, and the compound disclosed by the invention has good inhibitory activity on the pathogenic bacteria, such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957 and Staphylococcus aureus. The carbazole derivative has the characteristics of simple structure, easiness in synthesis, low price, wide application and the like, and has further research and development values in the aspect of preventing and treating the cow mastitis.

The invention relates to the technical field of biology, in particular to a detection method for tilapia streptococcus agalactiae resistance, a KASP primer group and application. According to the invention, the key SNP site of the ABCB4 gene, which is obviously associated with the streptococcus agalactiae disease resistance, of the tilapia is identified by a population genetics method, a typing method of the SNP site is developed by a KASP technology, efficient evaluation on disease resistance characters is realized, experimental data shows that the survival time of an AA genotype individual in a challenge test is prolonged compared with that of a GA / GG genotype individual, and the survival time of the AA genotype individual in the challenge test is obviously prolonged compared with that of a GA / GG genotype individual. The proportion of resistant fishes is remarkably increased, and genotype frequency distribution is strongly related to group disease resistance. According to the breeding strategy based on the SNP marker, the disease resistance of bred groups can be integrally improved, the morbidity and death rate are reduced, an efficient genetic improvement tool is provided for breeding of tilapia mossambica for resisting streptococcus agalactiae diseases, the loss of breeding diseases is reduced, and antibiotic dependence is reduced.

The invention relates to the technical field of biology, in particular to a tilapia mossambica streptococcus agalactiae resistance related KASP molecular marker and application thereof. According to the invention, two SNP (Single Nucleotide Polymorphism) loci, namely SNP-1 and SNP-2, which are remarkably associated with resistance are screened based on an intron region of an EGFRX2 gene of tilapia mossambica, a typing method of the loci is developed through a KASP technology, and relevance between the genotype of the SNP-1 and a resistance phenotype is verified. Furthermore, streptococcus agalactiae resistance dominant diplotype individuals are screened in combination with double SNP loci, and the survival rate of a challenge experiment is remarkably improved. The detection kit provided by the invention can realize high-throughput and high-precision typing, is suitable for tilapia mossambica resistance genotype identification and molecular marker-assisted breeding, provides an efficient genetic improvement tool for tilapia mossambica disease-resistant breeding, and is beneficial to reduction of breeding disease loss and reduction of antibiotic dependence.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The application discloses a kind of fluorescence colorimetric double-mode detection streptococcus agalactiae without aerosol pollution method, comprising the following steps: (1) strain culture and DNA extraction;(2) the combination of UDG and LAMP;(3) UDG-LAMP-CRISPR fluorescence mode detection system;(4) colorimetric mode detection system: read image RGB value in G value, G value significantly increases, and it is positive result.This patent innovatively combines UDG, LAMP, CRISPR and G4, introduces connection probe to realize "fluorescence-colorimetric" single system double-mode detection.The two detection modes of the detection platform can be freely split or combined, and can meet the needs of different detection environments.By combining UDG system and LAMP technology, aerosol pollution possibly carried in amplification process is avoided.Connection probe is introduced, CRISPR fluorescence detection is combined with G4 colorimetric detection, a detection system with "fluorescence-colorimetric" two detection modes is established, which is used for quantitative identification and cross verification of streptococcus agalactiae.

The present invention relates to an immunogenic polysaccharide-protein conjugate comprising a capsular polysaccharide (CP) from Streptococcus agalactiae (commonly known as group B streptococcus (GBS)) and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the sialic acid level of the CP is higher than about 60%. The present invention also relates to methods of making the conjugate and immunogenic compositions comprising the conjugate. The present invention also relates to an immunogenic composition comprising a polysaccharide-protein conjugate, wherein the conjugate comprises CP from GBS serotype IV and at least one additional serotype. The present invention further relates to methods of using the compositions disclosed herein to induce an immune response against GBS in a subject and / or to reduce or prevent invasive GBS disease in a subject. The antibodies generated can be used for the treatment or prevention of GBS infection by passive immunotherapy.

The invention discloses a method for evaluating streptococcus agalactiae resistance of genetically improved farmed tilapia. According to the invention, firstly, DNA methylation difference analysis is carried out aiming at the streptococcus agalactiae resistance traits of the genetically improved farmed tilapia, a DNA methylation molecular marker lcp2a308-485 associated with the traits is developed on the basis, and a pair of methylation marker detection primers associated with the streptococcus agalactiae resistance traits of the genetically improved farmed tilapia is provided. The methylation degree of the DNA methylation molecular marker lcp2a308-485 of a plasma cfDNA sample of Oreochromis niloticus has good correlation with the resistance of Streptococcus lactis, and the DNA methylation molecular marker can be used for noninvasive or minimally invasive detection of the resistance of Streptococcus lactis and can be used for breeding of sex Streptococcus lactis resistant Oreochromis niloticus. The breeding efficiency can be greatly improved, the practical problems of long breeding period, high input cost and the like in traditional disease resistance breeding can be solved, and the method has important significance on industrial development of genetically improved farmed tilapia mossambica.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The invention discloses a lactobacillus plantarum bacteriostatic agent and application thereof, and relates to the technical field of microbial engineering. According to the lactobacillus plantarum LP2301 provided by the invention, fermentation liquor of the lactobacillus plantarum LP2301 can be used for effectively inhibiting aquatic pathogenic bacteria streptococcus agalactiae, limiting the growth of the streptococcus agalactiae, reducing the use of antibiotics, ensuring food safety and guaranteeing the health of animals and human beings by secreting metabolites such as bacteriostatic proteins and organic acids. Secondly, the invention provides an application of the lactobacillus plantarum bacteriostatic agent, and the lactobacillus plantarum LP2301 is compounded into the bacteriostatic agent; through multi-target cooperation of the cortex phellodendri extract and the rosmarinic acid, the antibacterial efficiency of single probiotics is remarkably optimized; active ingredients of cortex phellodendri directionally destroy a biological membrane barrier of streptococcus agalactiae and disintegrate an adhesion defense system of pathogenic bacteria; rosmarinic acid blocks a bacterial energy metabolism pathway synchronously, so that pathogens lose proliferative power; and exclusive bacteriocin secreted by the LP2301 accurately breaks down a cell membrane structure, so that fatal killing is realized.

The application belongs to the technical field of Chinese herbal medicines, and particularly relates to a Chinese herbal medicine composition for resisting Streptococcus agalactiae, a preparation method and application thereof. Raw materials for preparing the Chinese herbal medicine composition include cortex mali and cumin. The Chinese herbal medicine composition is easy to obtain and simple to prepare, has no chemical residues, is not prone to drug resistance, has significant bacteriostatic activity on Streptococcus agalactiae, and can be applied to the prevention and treatment of Streptococcus agalactiae disease of fish such as tilapia.

The invention discloses a preparation method of a nano MOF (Metal Organic Framework)-SIP (Sequence Initicosus)-HP55 oral vaccine applied to streptococcus agalactiae infection of Nile tilapia. The nano MOF-SIP-HP55 oral vaccine comprises MOF-SIP (Sequence Initicosus) nanoparticles and an acid-base sensitive type enteric coating material HP55, wherein the surface of the MOF-SIP nanoparticles is coated with the acid-base sensitive type enteric coating material HP55; the MOF-SIP nano-particles are nano-materials formed by assembling streptococcus agalactiae surface protein SIP and a metal organic framework (MOF) nano-material. The nano vaccine provided by the invention has the advantages of good biocompatibility, degradability, safety, relatively high loading capacity, tolerance to digestion of fish gastric juice, immune response persistence, high effectiveness and the like, so that an effective technical support is provided for research and development of nano vaccines in the future, trend to clinical application and commercialization.

The present invention relates to a Lactobacillus delbrueckii subspecies and a culture method and application thereof. The Lactobacillus delbrueckii subspecies of the present invention is preserved in the China Center for Type Culture Collection, and its preservation number is CCTCCNO.M20221248. The Lactobacillus delbrueckii subspecies of the present invention is negative in a hydrogen peroxide test, can decompose sucrose and D-glucose, etc.; can produce a-hemolytic rings and antibacterial rings, can inhibit the growth of Staphylococcus aureus and Escherichia coli visible to the naked eye after being cultured on a blood plate for 48 hours, and can produce regular concentric circular hemolytic rings with Staphylococcus aureus; can inhibit the growth of Streptococcus agalactiae by producing acid on a culture medium; can decompose glycogen in vaginal epithelial cells to produce lactic acid, reduce pH value, inhibit the growth of pathogenic bacteria and excessive reproduction of conditional pathogens; is sensitive to 19 common antibacterial drugs, and is only resistant to sulfonamides; is suitable for the prevention or treatment of bacterial vaginal diseases, especially the prevention or treatment of bacterial vaginal diseases in pregnant women.

The present disclosure relates to the field of aptamers. More particularly, the present disclosure relates to aptamers for the specific binding of Group B Streptococcal (GBS) bacteria, such as Streptococcus agalactiae. Additionally, this disclosure relates to methods of using such aptamers in diagnosing, monitoring or treating diseases, disorders or conditions associated with GBS in patients.

The invention discloses a culture medium for detecting streptococcus agalactiae in bovine mastitis and a test piece thereof, the culture medium comprises a nutritional ingredient mixture, a composite inhibitor, a composite chromogenic enzyme substrate and cold water gel, the composite inhibitor is aztreonam, nalidixic acid, potassium clavulanate and trimethoprim; the compound chromogenic enzyme substrate is 5-bromine-6-chloro-3-indole-phosphoric acid p-toluidine, 5-bromine-4-chloro-3-indole-beta-D-glucuronide, 5-bromine-6-chloro-3-indole-beta-D-glucopyranoside, and 5-bromine-6-chloro-3-indole-beta-D-galactoside, and the compound chromogenic enzyme substrate is a compound chromogenic enzyme. The composite inhibitor in the streptococcus agalactiae test piece can effectively inhibit growth of non-target bacteria, and the composite chromogenic enzyme substrate has higher selectivity on target bacteria, so that the test piece has the characteristics of high specificity, high sensitivity, short detection period, easiness in observation and low detection cost; the method has huge development potential and wide application prospect in pasture detection.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention belongs to the technical field of gene engineering, and particularly relates to streptococcus agalactiae Mu-20 and a construction method and application thereof. The fish-derived streptococcus agalactiae which is lack of capsular polysaccharide, free of hyaluronidase activity, free of hemolysis and negative in trehalose fermentation is constructed, the strain number is Mu-20, the fish-derived streptococcus agalactiae is preserved in Guangdong Microbial Culture Collection Center on June 13, 2022, and the preservation number is GDMCC No: 62540; the strain does not carry chloramphenicol resistance marker genes, is high in biological safety, has no risk of virulence enhancement, is high in immunogenicity, and can protect immunized fish from resisting invasion of streptococcus agalactiae, and meanwhile, the attenuated live vaccine is easy to culture, simple to use and low in production cost; the strain provided by the invention can be used for preparing attenuated live vaccines for fish streptococcosis, and has extremely high commercial application value.

The invention discloses lactobacillus acidophilus BT-C15 with inflammation relieving and mucosal barrier repairing functions and application of the lactobacillus acidophilus BT-C15, the lactobacillus acidophilus BT-C15 is preserved in the China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252625. The invention provides a brand new lactobacillus acidophilus BT-C15 which mainly has the effects of relieving inflammation and whitening the skin. The lactobacillus acidophilus BT-C15 has good tolerance to gastric juice and intestinal juice, is high in cell adhesion capacity, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter Korotkoff, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can improve colitis, fade spots, whiten skin and improve autism, especially when the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 are used in a combined mode, the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 have a synergistic effect, and the improvement effect on the autism can be remarkably improved.

A method for rapidly identifying highly virulent strains of Streptococcus agalactiae, comprising: using a laser confocal Raman spectrometer to collect single-cell Raman spectra of clinical strains, and establishing a database; classifying data of III / ST17-type highly virulent GBS strains into a first group, named as GBS-HIGH, data of non-III / ST17-type GBS strains into a second group, named as GBS-OTHERS, and data of Escherichia coli into a third group, named as ECO; randomly dividing the three groups of data into a training set, a validation set and a test set in a ratio of 7:1:2; and on the basis of a ResNet18 residual neural network architecture, changing 2D convolution in a network to one-dimensional (1D) convolution suitable for a 1D Raman spectrum, determining optimal parameters by means of simulation experiments, training the weight of a model in the training set, and then selecting optimal hyperparameters by means of a result of the model on the verification set, so as to determine a trained model.

The application discloses a kind of nanobody targeting streptococcus agalactiae SIP protein and preparation and application thereof, it is related to biotechnology field, and the nanobody that the present application is screened by nanobody phage library construction, phage screening technology, and is efficiently and specifically combined with SIP protein Nanobody, the nanobody of streptococcus agalactiae SIP protein includes VHH fragment, with the amino acid sequence shown in SEQ ID NO:1.The nanobody can be combined with streptococcus agalactiae SIP protein high specificity, and the antibody can be targeted to SIP protein by the antibody, and the application discloses a kind of nanobody targeting streptococcus agalactiae SIP protein can be applied to fish disease diagnosis and treatment.

The application provides a tilapia antibacterial peptide OnLEAP-2 and an application thereof, and an antibacterial peptide named OnLEAP-2 is cloned from tilapia, and a large amount of the antibacterial peptide is obtained through prokaryotic expression. The antibacterial peptide has a good effect of resisting Streptococcus agalactiae, so that the survival rate of the tilapia is significantly improved, and pathogens are efficiently removed. The antibacterial peptide is suitable for the prevention and treatment of bacterial diseases of economic fishes such as tilapia.